Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Deffered Revenue (2023 - 2024)

Immunome (IMNM) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $2.2 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Non-Current Deffered Revenue fell 76.56% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Mar 2024, down 76.56%, and an annual FY2023 reading of $5.5 million, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $2.2 million for Q1 2024 at Immunome, down from $5.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $9.4 million in Q1 2023 and bottomed at $2.2 million in Q1 2024.